Gritstone bio Publishes Interim Results From Phase 1 Study Of Self-Amplifying mRNA Vaccine Against COVID-19 In Nature Communications
Portfolio Pulse from Benzinga Newsdesk
Gritstone bio has published interim results from its Phase 1 study of a self-amplifying mRNA vaccine against COVID-19 in Nature Communications. The results show promising safety and immunogenicity data.
June 08, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gritstone bio's interim results from the Phase 1 study of its self-amplifying mRNA COVID-19 vaccine show promising safety and immunogenicity data, potentially boosting investor confidence.
The interim results from Gritstone bio's Phase 1 study show promising safety and immunogenicity data for its self-amplifying mRNA COVID-19 vaccine. This positive news may lead to increased investor confidence in the company and its stock, resulting in a short-term positive impact on GRTS stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100